A3P Biomedical (“A3P”) today announces that Chief Executive Officer (“CEO”) David Rosén is leaving his position to pursue other opportunities outside the Group. Executive Chairman Martin Steinberg will lead the company from June 1, with Ola Steinberg as CEO until the appointment of a new CEO.
“The Board extends its gratitude to David for his valuable contribution to A3P over the past three years as the company’s CEO. His efforts in building the internal infrastructure and strengthening the team has established a robust foundation for accelerated business expansion. We wish him all the best in his future endeavors,” says Martin Steinberg, Chairman of the Board.
With market presence in Switzerland, Germany, and the USA, A3P is entering a new phase. The focus is to expand the business in these and other markets by establishing partnerships and alliances, driving sales, attracting sales and marketing talent, all with the aim of establishing Stockholm3 as the standard of care for early detection of aggressive prostate cancer.
“As we enter the next phase of our growth journey, we are rapidly moving towards a SaaS model both in Europe and the USA, which places high and partly new demands on us. Succeeding in the USA is of the highest priority. Therefore, we will be seeking a CEO with a proven track record and experience in driving accelerated international expansion within life science – to take us to the next level,” Martin Steinberg concludes.